

Supplementary Materials

Copper-Catalyzed Intramolecular Olefinic C(sp²)–H Amidation for the Synthesis of γ -Alkylidene- γ -lactams

Kanako Nozawa-Kumada^{1,2,*}, Masahito Hayashi¹, Eunsang Kwon^{3,4}, Masanori Shigeno^{1,5}, Akira Yada² and Yoshinori Kondo¹

¹ Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan

² Interdisciplinary Research Center for Catalytic Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Central 5, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan

³ Endowed Research Laboratory of Dimensional Integrated Nanomaterials, Graduate School of Science, Tohoku University, Aoba-ku, Sendai, Miyagi 980-8578, Japan

⁴ Research and Analytical Center for Giant Molecules, Graduate School of Science, Tohoku University, Aoba-ku, Sendai, Miyagi 980-8578, Japan

⁵ Japan Science and Technology Agency (JST), Precursory Research for Embryonic Science and Technology (PRESTO), Kawaguchi, Saitama 332-0012, Japan

* Correspondence: k.kumada@aist.go.jp; Tel.: +81-29-861-5908

Table of Contents

1. General comments	S3
2. Materials	S3
3. Preparation of starting materials	S3
4. General procedure for the synthesis of 5-alkylidene-pyrrolin-2-ones	S13
5. General procedure for the synthesis of 5-alkylidene-pyrrolidin-2-ones	S21
6. Mechanistic experiment	S30
7. X-ray crystallographic data for 4a	S31
8. ^1H-, ^{13}C-, and ^{19}F-NMR spectra	S34

1. General comments


Melting points were measured with a Yazawa micro melting point apparatus and uncorrected. IR spectra were recorded on a SHIMADZU IRAffinity. ¹H NMR spectra were recorded on a JEOL JNMAL400 (400 MHz) spectrometer or a JEOL ECA600 (600 MHz) spectrometer. Chemical shifts are expressed in δ (parts per million, ppm) values and coupling constants are expressed in hertz (Hz). ¹H NMR spectra were referenced to tetramethylsilane as an internal standard or to a solvent signal (CDCl_3 : 7.26 ppm, $\text{DMSO}-d_6$: 2.49 ppm). ¹³C NMR spectra were referenced to a solvent signal (CDCl_3 : 77.0 ppm, $\text{DMSO}-d_6$: 39.5 ppm). ¹⁹F NMR spectra were referenced to 4-fluorotoluene as an internal standard (-118.0 ppm). All NMR spectra were measured at 25 °C using a 5 mm diameter glass NMR tube. The following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, dd, = double doublet, m = multiplet, and br.s. = broad singlet. Low and high resolution mass spectra (LRMS and HRMS) were obtained from Mass Spectrometry Resource, Graduate School of Pharmaceutical Sciences, Tohoku University, on a JEOL JMS-DX 303 and JMS700/JMS-T 100 GC spectrometer. HRMS were performed using polyethylene glycol (PEG) or perfluorokerosene (PEK) as an internal standard and 3-nitrobenzyl alcohol (3-NBA) or glycerol (GLY) as matrix. The Bruker D8 VENTURE x-ray diffractometer was used to determine the structure of the grown crystals.

2. Materials

Materials were purchased from Tokyo Kasei Co., Aldrich Inc. and other commercial suppliers and were used as received. Flash column chromatography was performed with Kanto silica gel 60 N (spherical, neutral, 70–230 mesh).

3. Preparation of starting materials

Method A




Step 1: (3-Carboxypropyl)triphenylphosphonium bromide (2.1 g, 5.0 mmol) was suspended in THF (20 mL). The colorless suspension was cooled to 0 °C and NaHMDS (1.1 M in hexane, 12.5 mL, 13.8 mmol) was added dropwise. Then, the resulting bright orange solution was stirred at 0 °C for 30 min. To the reaction mixture was added a solution of ketone (6.0 mmol) in THF (10

mL) dropwise at 0 °C and the reaction mixture was stirred overnight at rt. The reaction mixture was diluted with 1M HCl to pH 1, then extracted with AcOEt (20 mL x 3). The organic layers were washed with brine (10 mL) and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by SiO₂ column chromatography (eluent: hexane/AcOEt = 3/1).

Step 2: To a solution of the carboxylic acid (3.0 mmol) in dichloromethane (10 mL) were added dimethylformamide (2 drops) and oxalyl chloride (0.53 mL, 3.8 mmol) at -78 °C under N₂ atmosphere. The resulting mixture was stirred overnight at rt. The solvent was then removed under reduced pressure to afford the corresponding crude acyl chloride. To a stirred solution of the acyl chloride in THF (10 mL), aniline derivative (3.6 mmol) and triethylamine (1.3 mL, 9.0 mmol) were added dropwise using a dropping funnel at -100 or -78 °C. After complete addition, the reaction mixture was stirred for 6 h at rt. The solvent was then removed under reduced pressure and 3 M HCl aq. (10 mL) was added to the mixture. The resulting solution was extracted with AcOEt (10 mL x 3). The organic layers were washed with sat. Na₂CO₃ aq. (10 mL) and brine (10 mL). The solvent was dried over MgSO₄ and removed under reduced pressure. The residue was recrystallization to give the corresponding amide compound.

Method B




Step 1: (3-Carboxypropyl)triphenylphosphonium bromide (2.1 g, 5.0 mmol) was suspended in THF (20 mL). The colorless suspension was cooled to 0 °C and NaHMDS (1.1 M in hexane, 12.5 mL, 13.8 mmol) was added dropwise. Then, the resulting bright orange solution was stirred at 0 °C for 30 min. To the reaction mixture was added a solution of ketone (6.0 mmol) in THF (10 mL) dropwise at 0 °C and the reaction mixture was stirred overnight at rt. The reaction mixture was diluted with 1M HCl to pH 1, then extracted with AcOEt (10 mL x 3). The organic layers were washed with brine (15 mL) and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by SiO₂ column chromatography (eluent: hexane/AcOEt = 3/1).

Step 2: To a solution of the carboxylic acid (3.0 mmol) in dichloromethane (10 mL) were added EDC·HCl (690.1 mg, 3.6 mmol), *N,N*-dimethylaminopyridine (366.5 mg, 3.0 mmol), and amine

(3.3 mmol) at rt under N₂ atmosphere. The resulting mixture was stirred overnight at rt. After completion of the reaction, water (10 mL) was added to the reaction mixture. The resulting solution was extracted with AcOEt (20 mL x 3). The organic layers were washed with brine (10 mL). The solvent was dried over MgSO₄ and removed under reduced pressure. The residue was recrystallization to give the corresponding amide compound.

Method C




Step 1: (3-Ethoxycarbonylpropyl)triphenylphosphonium bromide (457.0 mg, 1.0 mmol) was suspended in THF (5 mL). The colorless suspension was cooled to -78 °C and NaHMDS (1.1 M in hexane, 1.2 mL, 1.2 mmol) was added dropwise. Then, the resulting bright orange solution was stirred at 0 °C for 30 min. To the reaction mixture was added a solution of ketone (1.1 mmol) in THF (5 mL) dropwise at 0 °C and the reaction mixture was stirred overnight at rt. The reaction mixture was diluted with 1M HCl (10 mL) and extracted with AcOEt (10 mL x 3). The organic layers were washed with brine (15 mL) and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by SiO₂ column chromatography (eluent: hexane/AcOEt = 3/1).

Step 2: After the purification, to a solution of the ester (1.0 mmol) in EtOH (10 mL) were added NaOH (2.0 g) and H₂O (5 mL) at rt under air atmosphere. The resulting mixture was stirred at reflux overnight. After completion of the reaction, the mixture was cooled to rt and diluted with water (10 mL) and conc. HCl (10 mL). The resulting solution was extracted with AcOEt (10 mL x 3). The organic layers were washed with brine (10 mL). The solvent was dried over MgSO₄ and removed under reduced pressure. The residue was purified by SiO₂ column chromatography (eluent: hexane/AcOEt = 2/1).

Step 3: The next amidation was conducted according to Step 2 of Method B.


N,5,5-Triphenylpent-4-enamide (1a)



Prepared according to Method A, 2.0 g (60% over 2 steps, 10.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 139–140 °C.

¹H NMR (400 MHz, CDCl₃/TMS) δ (ppm): 7.47 (2H, d, *J* = 7.8 Hz), 7.38–7.18 (12H, m), 7.11–7.04 (2H, m), 6.13 (1H, t, *J* = 7.6 Hz), 2.56 (2H, t, *J* = 7.2 Hz), 2.48 (2H, t, *J* = 7.2 Hz); ¹³C{¹H} NMR (100 MHz, CDCl₃/TMS) δ (ppm): 170.4, 143.2, 142.2, 139.6, 137.8, 129.7, 128.9, 128.3, 128.1, 127.23, 127.19, 127.1, 124.2, 119.8, 111.3, 37.6, 25.8; LRMS (EI) *m/z*: 327 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₂₁NO: 327.1623, found: 327.1606; IR (neat): 3317, 3296, 1656, 1601, 1542, 1533, 1490, 1442, 763, 755, 743 cm⁻¹.


5,5-Bis(4-methoxyphenyl)-N-phenylpent-4-enamide (1b)



Prepared according to Method A, 1.2 g (61% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless powder, mp. 158–160 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.46 (2H, d, *J* = 7.6 Hz), 7.29 (2H, t, *J* = 7.9 Hz), 7.18–7.13 (3H, m), 7.10–7.06 (3H, m), 6.89 (2H, d, *J* = 8.9 Hz), 6.79 (2H, d, *J* = 8.2 Hz), 5.96 (1H, t, *J* = 7.2 Hz), 3.82 (3H, s), 3.78 (3H, s), 2.55 (2H, q, *J* = 7.4 Hz), 2.45 (2H, t, *J* = 7.4 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.4, 158.9, 158.7, 142.4, 137.8, 135.3, 132.1, 130.9, 129.0, 128.4, 125.3, 124.2, 119.8, 113.7, 113.5, 55.3, 55.2, 37.9, 25.8; LRMS (EI) *m/z*: 387 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₂₅NO₃: 387.1834, found: 387.1820; IR (neat): 3296, 2834, 1649, 1607, 1509, 1439, 1247, 1176, 1031, 837 cm⁻¹.


N-Phenyl-5,5-di-p-tolylpent-4-enamide (1c)



Prepared according to Method B, 230.2 mg (22% over 2 steps, 3.0 mmol scale), recrystallized from DCM/hexane, colorless plates, mp. 119–120 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.46 (2H, d, *J* = 8.0 Hz), 7.29 (2H, t, *J* = 7.8 Hz), 7.17 (2H, d, *J* = 7.5 Hz), 7.11–7.05 (8H, m), 6.04 (1H, t, *J* = 7.5 Hz), 2.55 (2H, q, *J* = 7.3 Hz), 2.45 (2H, t, *J* = 7.3 Hz), 2.37 (3H, s), 2.31 (3H, s); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.4, 143.1, 139.7, 137.8, 136.9, 136.81, 136.79, 129.7, 129.00, 128.96, 128.8, 127.2, 126.1, 124.2, 119.8, 37.8, 25.8, 21.2, 21.0; LRMS (EI) *m/z*: 355 (M⁺); HRMS (EI-EB) Calcd. for C₂₅H₂₅NO: 355.1936, found: 355.1941; IR (neat): 3290, 3017, 2861, 1649, 1600, 1526, 1443, 817 cm⁻¹.


5,5-Bis(4-fluorophenyl)-N-phenylpent-4-enamide (1d)



Prepared according to Method A, 1.0 g (57% over 2 steps, 5.0 mmol scale), recrystallized from DCM /hexane, colorless needles, mp. 133–135 °C.

¹H NMR (400 MHz, CDCl₃/TMS) δ (ppm): 7.47 (2H, d, *J* = 8.3 Hz), 7.30 (2H, t, *J* = 8.1 Hz), 7.18–7.03 (8H, m), 6.94 (2H, t, *J* = 8.8 Hz), 6.04 (1H, t, *J* = 7.1 Hz), 2.55–2.44 (4H, m); ¹³C{¹H} NMR (100 MHz, CDCl₃/TMS) δ (ppm): 170.3, 162.1 (¹J_{C-F} = 245.3 Hz), 162.0 (¹J_{C-F} = 245.3 Hz), 141.1, 138.3 (⁴J_{C-F} = 3.3 Hz), 137.7, 135.3 (⁴J_{C-F} = 3.3 Hz), 131.3 (³J_{C-F} = 8.2 Hz), 128.9, 128.8 (³J_{C-F} = 8.2 Hz), 127.5, 124.3, 119.8, 115.3 (²J_{C-F} = 20.6 Hz), 115.0 (²J_{C-F} = 21.4 Hz), 37.4, 25.7; ¹⁹F NMR (565 MHz, CDCl₃) δ (ppm): -114.0, -114.7; LRMS(EI) *m/z*: 363 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₉F₂NO (M⁺): 363.1435, found: 363.1423; IR (neat): 3286, 1654, 1601, 1506, 1501, 1222, 843, 749, 742 cm⁻¹.


5,5-Bis(4-chlorophenyl)-N-phenylpent-4-enamide (1e)



Prepared according to Method A, 1.3 g (65% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 148–149 °C.

¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm): 9.89 (1H, br.s), 7.60–7.52 (2H, m), 7.45 (2H, d, *J* = 6.8 Hz), 7.34–7.33 (2H, m), 7.27 (2H, t, *J* = 7.9 Hz), 7.16–7.14 (4H, m), 7.00 (1H, t, *J* = 7.6 Hz), 6.19 (1H, t, *J* = 7.6 Hz), 2.45–2.43 (2H, m), 2.35–2.34 (2H, m); ¹³C{¹H} NMR (150 MHz, DMSO-*d*₆) δ (ppm): 170.3, 140.4, 139.2, 139.1, 137.7, 132.1, 131.8, 131.3, 129.8, 128.6, 128.52, 128.48, 128.3, 123.0, 119.0, 36.1, 25.7; LRMS (EI) *m/z*: 395 (M⁺); HRMS(EI-TOF) Calcd. for C₂₃H₁₉³⁵Cl₂NO: 395.0844, found: 395.0816; IR (neat): 3299, 1654, 1600, 1521, 1488, 1442, 1093, 1016, 828, 759, 753 cm⁻¹.


N-Phenyl-5,5-bis(4-(trifluoromethyl)phenyl)pent-4-enamide (1f)



Prepared according to Method A, 665.5 mg (29% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 153–155 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.64 (2H, d, *J* = 8.2 Hz), 7.51 (2H, d, *J* = 8.9 Hz), 7.47 (2H, d, *J* = 8.2 Hz), 7.32–7.26 (6H, m), 7.11 (2H, t, *J* = 7.2 Hz), 6.26 (1H, t, *J* = 7.2 Hz), 2.56 (2H, q, *J* = 7.1 Hz), 2.50 (2H, t, *J* = 7.1 Hz); ¹³C{¹H, ¹⁹F} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 169.8, 144.9, 142.7, 140.9, 137.6, 130.6, 130.1, 129.8, 129.4, 129.1, 127.4, 125.6, 125.3, 124.5, 124.11, 124.07, 119.8, 37.1, 25.7; ¹⁹F NMR (565 MHz, CDCl₃/TMS) δ (ppm): -61.87, -61.89; LRMS (EI) *m/z*: 463 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₁₉F₆NO: 463.1371, found: 463.1399; IR (neat): 3312, 1658, 1600, 1532, 1501, 1324, 1104, 1068, 834, 707 cm⁻¹.

N-Phenyl-4-(9*H*-xanthen-9-ylidene)butanamide (1g)




Prepared according to Method C, 142.4 mg (14% over 3 steps, 3.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 141–143 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.58 (1H, d, *J* = 7.5 Hz), 7.52 (1H, d, *J* = 7.5 Hz), 7.49 (2H, d, *J* = 8.0 Hz), 7.33–7.29 (3H, m), 7.27–7.24 (1H, m), 7.18–7.09 (6H, m), 5.87 (1H, t, *J* = 7.0 Hz), 3.01 (2H, q, *J* = 7.4 Hz), 2.58 (2H, t, *J* = 7.4 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.2, 152.9, 151.3, 137.7, 129.0, 128.8, 128.3, 127.9, 127.6, 125.4, 124.3, 123.9, 123.8, 123.5, 122.9, 122.2, 119.8, 116.7, 116.5, 38.0, 25.6; LRMS (EI) *m/z*: 341 (M⁺);

HRMS (EI-TOF) Calcd. for C₂₃H₁₉NO₂: 341.1416, found: 341.1413; IR (neat): 3293, 1648, 1601, 1477, 1451, 1256, 868 cm⁻¹.


4-(5H-Dibenzo[*a,d*][7]annulen-5-ylidene)-*N*-phenylbutanamide (1h)



Prepared according to Method A, 607.9 mg (35% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless crystals, mp. 164–167 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.43 (2H, d, *J* = 7.6 Hz), 7.36–7.24 (10H, m), 7.08 (1H, t, *J* = 7.6 Hz), 7.01 (1H, br.s), 6.84–6.80 (2H, m), 5.60 (1H, dd, *J* = 9.0, 5.5 Hz), 2.65–2.61 (1H, m), 2.50–2.46 (1H, m), 2.40–2.35 (2H, m); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.2, 143.0, 142.2, 137.7, 136.9, 134.7, 133.9, 131.7, 131.2, 131.0, 128.9, 128.80, 128.78, 128.7, 128.25, 128.18, 127.6, 127.1, 127.0, 124.2, 119.9, 37.6, 24.7; LRMS (EI) *m/z*: 351 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₂₁NO: 351.1623, found: 351.1605; IR (neat): 3019, 1704, 1487, 1432, 1208, 924, 796 cm⁻¹.


***N*-(4-Methoxyphenyl)-5,5-diphenylpent-4-enamide (1i)**



Prepared according to Method A, 1.0 g (58% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless powder, mp. 144–147 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.36–7.34 (4H, m), 7.31–7.28 (2H, m), 7.25–7.19 (5H, m), 7.16 (2H, d, *J* = 7.5 Hz), 6.81 (2H, d, *J* = 8.9 Hz), 6.10 (1H, t, *J* = 7.2 Hz), 3.75 (3H, s), 2.53 (2H, q, *J* = 7.6 Hz), 2.42 (2H, t, *J* = 7.6 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.2, 156.3, 143.1, 142.3, 139.7, 130.9, 129.7, 128.3, 128.1, 127.4, 127.24, 127.18, 127.1, 121.7, 114.1, 55.4, 37.4, 25.8; LRMS (EI) *m/z*: 357 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₂₃NO₂ (M⁺): 357.1729, found: 357.1721; IR (neat): 3288, 2835, 1652, 1609, 1510, 1246, 1031, 831 cm⁻¹;


5,5-Diphenyl-*N*-(*p*-tolyl)pent-4-enamide (1j)



Prepared according to Method A, 1.2 g (69% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless crystals, mp. 136–138 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.37–7.30 (5H, m), 7.26–7.24 (2H, m), 7.22–7.20 (3H, m), 7.17 (2H, d, *J* = 7.0 Hz), 7.12 (1H, br.s), 7.09 (2H, d, *J* = 8.0 Hz), 6.11 (1H, t, *J* = 7.3 Hz), 2.54 (2H, q, *J* = 7.4 Hz), 2.44 (2H, t, *J* = 7.4 Hz), 2.29 (3H, s); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.2, 143.2, 142.3, 139.7, 135.2, 133.8, 129.8, 129.4, 128.3, 128.1, 127.3, 127.25, 127.20, 127.1, 119.9, 37.6, 25.8, 20.8; LRMS (EI) *m/z*: 341 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₂₃NO: 341.1780, found: 341.1762; IR (neat): 3293, 1655, 1601, 1525, 1496, 1442, 817, 764 cm⁻¹.


N-(4-Isopropylphenyl)-5,5-diphenylpent-4-enamide (1k)



Prepared according to Method A, 873.9 mg (47% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless powder, mp. 105–106 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.38–7.35 (4H, m), 7.31 (1H, t, *J* = 7.6 Hz), 7.26–7.14 (9H, m), 7.09 (1H, br.s), 6.11 (1H, t, *J* = 7.4 Hz), 2.86 (1H, sep, *J* = 6.8 Hz), 2.55 (2H, q, *J* = 7.4 Hz), 2.45 (2H, t, *J* = 7.4 Hz), 1.22 (6H, d, *J* = 6.8 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.2, 145.0, 143.2, 142.3, 139.7, 135.4, 129.8, 128.3, 128.1, 127.31, 127.26, 127.2, 127.1, 126.8, 120.0, 37.6, 33.6, 25.8, 24.0; LRMS (EI) *m/z*: 369 (M⁺); HRMS (EI-TOF) Calcd. for C₂₆H₂₇NO: 369.2093, found: 369.2082; IR (neat): 3296, 2962, 1652, 1598, 1516, 1256, 831, 773 cm⁻¹.

N-(4-Fluorophenyl)-5,5-diphenylpent-4-enamide (1l)




Prepared according to Method A, 1.2 g (70% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 120–122 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.40 (2H, dd, *J* = 8.9, 4.8 Hz), 7.36 (2H, t, *J* = 7.2 Hz), 7.32–7.29 (1H, m), 7.26–7.19 (6H, m), 7.16 (2H, d, *J* = 6.9 Hz), 6.97 (2H, t, *J* = 8.9 Hz), 6.09 (1H, t, *J* = 7.3 Hz), 2.54 (2H, q, *J* = 7.3 Hz), 2.44 (2H, t, *J* = 7.3 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.5, 159.3 (¹J_{C-F} = 242.0 Hz), 143.3, 142.2, 139.6, 133.81, 133.79, 129.7, 128.3, 128.1, 127.21, 127.16, 127.13, 121.7 (³J_{C-F} = 7.7 Hz), 115.5 (²J_{C-F} = 22.3 Hz), 37.4, 25.8; ¹⁹F NMR (565 MHz, CDCl₃) δ (ppm): -117.4; LRMS (EI) *m/z*: 345 (M⁺); HRMS (EI-TOF)

Calcd. for C₂₃H₂₀FNO: 345.1529, found: 345.1514; IR (neat): 3303, 1660, 1506, 1407, 1210, 831 cm⁻¹.


N-(4-Chlorophenyl)-5,5-diphenylpent-4-enamide (1m)



Prepared according to Method A, 631.1 mg (35% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 135–138 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.41 (2H, d, *J* = 8.3 Hz), 7.38–7.35 (2H, m), 7.33–7.30 (1H, m), 7.27–7.16 (9H, m), 7.12 (1H, br.s), 6.10 (1H, t, *J* = 7.4 Hz), 2.55 (2H, q, *J* = 7.4 Hz), 2.46 (2H, t, *J* = 7.4 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.3, 143.4, 142.2, 139.6, 136.3, 129.7, 129.2, 129.0, 128.4, 128.2, 127.3, 127.24, 127.22, 127.0, 121.0, 37.6, 25.7; LRMS (EI) *m/z*: 361 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₂₀³⁵ClNO (M⁺): 361.1233, found: 361.1204; IR (neat): 3310, 1660, 1594, 1515, 1491, 1397, 1091, 821 cm⁻¹.


N-(4-Bromophenyl)-5,5-diphenylpent-4-enamide (1n)



Prepared according to Method A, 1.0 g (49% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, yellow plates, mp. 156–158 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.40–7.35 (6H, m), 7.32–7.30 (1H, m), 7.26–7.19 (6H, m), 7.16 (2H, d, *J* = 7.6 Hz), 6.09 (1H, t, *J* = 7.3 Hz), 2.54 (2H, q, *J* = 7.3 Hz), 2.45 (2H, t, *J* = 7.3 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.4, 143.43, 143.42, 142.1, 139.6, 136.8, 131.9, 129.7, 128.4, 128.1, 127.3, 127.2, 127.0, 121.3, 116.8, 37.6, 25.7; LRMS (EI) *m/z*: 405 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₂₀⁷⁹BrNO: 405.0728, found: 405.0701; IR (neat): 3291, 1659, 1598, 1521, 1490, 1396, 1303, 1070 cm⁻¹.


5,5-Diphenyl-N-(4-(trifluoromethyl)phenyl)pent-4-enamide (1o)



Prepared according to Method B, 1.1 g (58% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 124–126 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.59 (2H, d, *J* = 8.9 Hz), 7.55 (2H, d, *J* = 8.3 Hz), 7.37 (2H, t, *J* = 7.6 Hz), 7.33–7.31 (1H, m), 7.27–7.20 (6H, m), 7.18–7.16 (2H, m), 6.11 (1H, t, *J* = 7.1 Hz), 2.56 (2H, q, *J* = 7.1 Hz), 2.49 (2H, t, *J* = 7.1 Hz); ¹³C{¹H, ¹⁹F} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.7, 143.6, 142.1, 140.8, 139.6, 129.7, 128.4, 128.2, 127.3, 127.25, 127.22, 126.8, 126.2, 126.0, 124.0, 119.3, 37.7, 25.6; ¹⁹F NMR (565 MHz, CDCl₃/TMS) δ (ppm): –61.5; LRMS (EI) *m/z*: 395 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₂₀F₃NO (M⁺): 395.1497, found: 395.1490; IR (neat): 3333, 1669, 1601, 1522, 1326, 1112, 1067, 1017, 833 cm⁻¹.


N-(4-Cyanophenyl)-5,5-diphenylpent-4-enamide (1p)



Prepared according to Method B, 755.5 mg (42% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless powder, mp. 142–143 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.61–7.58 (4H, m), 7.37 (2H, t, *J* = 7.2 Hz), 7.34–7.31 (1H, m), 7.27–7.23 (4H, m), 7.20 (2H, d, *J* = 8.3 Hz), 7.17–7.16 (2H, m), 6.10 (1H, t, *J* = 7.2 Hz), 2.56 (2H, q, *J* = 7.2 Hz), 2.51 (2H, t, *J* = 7.2 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.6, 143.7, 142.0, 141.8, 139.5, 133.3, 129.7, 128.4, 128.2, 127.34, 127.32, 127.2, 126.6, 119.4, 118.8, 107.1, 37.8, 25.5; LRMS (EI) *m/z*: 352 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₂₀N₂O: 352.1576, found: 352.1583; IR (neat): 3106, 2220, 1665, 1594, 1498, 1408, 1173 cm⁻¹.


Methyl 4-(5,5-diphenylpent-4-enamido)benzoate (1q)



Prepared according to Method A, 927.1 mg (48% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless needles, mp. 120–123 °C.

¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm): 10.3 (1H, s), 7.89 (2H, d, *J* = 9.0 Hz), 7.70 (2H, d, *J* = 9.0 Hz), 7.39 (2H, t, *J* = 7.5 Hz), 7.33 (1H, t, *J* = 7.5 Hz), 7.27 (2H, t, *J* = 7.3 Hz), 7.21 (1H, t, *J* = 7.3 Hz), 7.15–7.12 (4H, m), 6.12 (1H, t, *J* = 7.4 Hz), 3.80 (3H, s), 2.50–2.48 (2H, m), 2.36 (2H, q, *J* = 7.4 Hz); ¹³C{¹H} NMR (150 MHz, DMSO-*d*₆) δ (ppm): 171.1, 165.8, 143.5, 141.9, 141.6, 139.4, 130.2, 129.4, 128.3, 128.2, 128.0, 127.1, 127.0, 126.8, 123.7, 118.3, 51.8, 36.5, 25.5; LRMS (EI) *m/z*: 385 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₂₃NO: 385.1678, found: 385.1706; IR (neat): 3324, 2952, 1715, 1676, 1590, 1517, 1406, 1310, 1281, 1109, 856, 767 cm⁻¹.


N-(3-Bromophenyl)-5,5-diphenylpent-4-enamide (1r)



Prepared according to Method B, 1.1 g (53% over 2 steps, 5.0 mmol scale), recrystallized from AcOEt/hexane, colorless plates, mp. 82–83 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.72 (1H, s), 7.39–7.37 (3H, m), 7.32 (1H, tt, *J* = 7.3, 1.7 Hz), 7.27–7.14 (9H, m), 7.08 (1H, br.s), 6.10 (1H, t, *J* = 7.3 Hz), 2.55 (2H, q, *J* = 7.3 Hz), 2.46 (2H, t, *J* = 7.3 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 170.5, 143.4, 142.1, 139.6, 139.0, 130.2, 129.7, 128.3, 128.1, 128.0, 127.3, 127.23, 127.19, 126.9, 122.7, 122.5, 118.2, 37.6, 25.6; LRMS (EI) *m/z*: 405 (M⁺); HRMS (EI-EB) Calcd. for C₂₃H₂₀⁷⁹BrNO: 405.0728, found: 405.0754; IR (neat): 3309, 1652, 1583, 1516, 1417, 874, 783 cm⁻¹.

N-(Benzo[d]thiazol-2-yl)-5,5-diphenylpent-4-enamide (1s)




Prepared according to Method B, 784.9 mg (41% over 2 steps, 5.0 mmol scale), recrystallized from DCM/hexane, colorless plates, mp. 173–175 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 11.2 (1H, br.s), 7.85 (1H, d, *J* = 8.0 Hz), 7.75 (1H, d, *J* = 8.0 Hz), 7.44 (1H, t, *J* = 7.5 Hz), 7.35–7.19 (7H, m), 7.13 (2H, d, *J* = 8.0 Hz), 7.06 (2H, d, *J* = 7.5 Hz), 5.98 (1H, t, *J* = 7.0 Hz), 2.59–2.51 (4H, m); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.0, 159.8, 147.7, 143.5, 142.1, 139.4, 131.9, 129.6, 128.3, 128.1, 127.21, 127.18, 127.15, 126.4, 126.3, 124.0, 121.7, 120.3, 36.5, 25.2; LRMS (EI) *m/z*: 384 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₂₀N₂OS: 384.1296, found: 384.1291; IR (neat): 3189, 3060, 1700, 1598, 1551, 1497, 1443, 1270, 1167, 768, 752 cm⁻¹.

4. General procedure for the synthesis of 5-alkylidene-pyrrolin-2-ones

In a glove box, an amide **1** (0.20 mmol), CuF₂ (2.0 mg, 0.020 mmol), 4-*tert*-butylpyridine (29.3 μL, 0.020 mmol), *t*BuOO*t*Bu (147.0 μL, 0.80 mmol), and 1,2-dichloroethane (2.5 mL) were added to a sealed tube. The mixture was stirred at 120 °C for 18 h. The reaction was diluted with water (10 mL) and extracted with chloroform (10 mL × 3). The organic layers were washed with brine (10 mL) and dried over MgSO₄. The solvent was removed under a reduced pressure and the residue was purified by SiO₂ column chromatography.


Table S1. Effect of reaction parameter for the synthesis of **2a**.



Entry	Copper salt	Base	Oxidant	Solvent	2a (%)^a
1	CuF ₂	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	1,2-DCE	76 (85)
2	CuCl	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	1,2-DCE	75
3	CuCl ₂	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	1,2-DCE	46
4	Cu(OAc) ₂	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	1,2-DCE	39
5	CuF ₂	Pyridine	tBuOO <i>t</i> Bu	1,2-DCE	66
6	CuF ₂	DMAP	tBuOO <i>t</i> Bu	1,2-DCE	44
7	CuF ₂	1,10-Phen	tBuOO <i>t</i> Bu	1,2-DCE	21
8	CuF ₂	None	tBuOO <i>t</i> Bu	1,2-DCE	29
9	CuF ₂	4- <i>tert</i> -Butylpyridine	tBuOOH	1,2-DCE	2
10	CuF ₂	4- <i>tert</i> -Butylpyridine	tBuOOAc	1,2-DCE	0
11	CuF ₂	4- <i>tert</i> -Butylpyridine	PIDA	1,2-DCE	35
12	CuF ₂	4- <i>tert</i> -Butylpyridine	MnO ₂	1,2-DCE	5
13	CuF ₂	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	DCM	0
14	CuF ₂	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	Toluene	44
15	CuF ₂	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	PhCF ₃	0
16 ^b	CuF ₂	4- <i>tert</i> -Butylpyridine	tBuOO <i>t</i> Bu	1,2-DCE	73

^a Determined by ¹H-NMR using 1,1,2-trichloroethane as an internal standard. Isolated yield in parentheses. ^b Reaction was conducted at 100 °C.


5-(Diphenylmethylene)-1-phenyl-1,5-dihydro-2H-pyrrol-2-one (**2a**)



Obtained as yellow needles in 85% (55.0 mg, 0.20 mmol scale), 87% (286.6 mg, 1.0 mmol scale), recrystallized from DCM/hexane, mp. 160–163 °C.

¹H NMR (400 MHz, CDCl₃/TMS) δ (ppm): 7.38–7.36 (3H, m), 7.26–7.23 (2H, m), 7.21 (1H, d, J = 5.8 Hz), 7.00–6.83 (10H, m), 6.28 (1H, d, J = 5.4 Hz); ¹³C{¹H} NMR (100 MHz, CDCl₃/TMS) δ (ppm): 171.8, 140.5, 140.3, 138.1, 137.9, 135.8, 131.6, 130.94, 130.89, 128.4, 128.0, 127.9, 127.7, 127.2, 127.1, 126.0, 121.7; LRMS (EI) *m/z*: 323 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₇NO: 323.1310, found: 323.1286; IR (neat): 3052, 1691, 1683, 1498, 1443, 1370, 1213, 1203, 1163, 1073, 968, 801, 774, 765, 756 cm⁻¹.


5-(Bis(4-methoxyphenyl)methylene)-1-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (2b)



Obtained as red crystals in 80% (61.5 mg), recrystallized from DCM/hexane, mp. 177–178 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.19–7.17 (3H, m), 7.01 (2H, t, *J* = 7.6 Hz), 6.97–6.94 (3H, m), 6.90 (2H, d, *J* = 8.9 Hz), 6.77 (2H, d, *J* = 8.9 Hz), 6.42 (2H, d, *J* = 8.9 Hz), 6.23 (1H, d, *J* = 5.5 Hz), 3.85 (3H, s), 3.66 (3H, s); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.9, 160.1, 159.3, 140.3, 136.8, 136.1, 133.1, 132.5, 131.0, 130.6, 127.8, 127.0, 125.73, 125.72, 120.6, 113.5, 112.7, 55.3, 55.2; LRMS (EI) *m/z*: 383 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₂₁NO₃: 383.1521, found: 383.1539; IR (neat): 1675, 1604, 1508, 1498, 1252, 1179, 1028, 969, 831 cm⁻¹.


5-(Di-*p*-tolylmethylene)-1-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (2c)



Obtained as colorless needles in 60% (42.4 mg), recrystallized from DCM/hexane, mp. 161–162 °C.


¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm): 7.21 (2H, d, *J* = 8.2 Hz), 7.18 (1H, d, *J* = 5.9 Hz), 7.11 (2H, d, *J* = 8.3 Hz), 6.99 (2H, t, *J* = 7.2 Hz), 6.94–6.91 (3H, m), 6.70 (2H, d, *J* = 8.2 Hz), 6.67 (2H, d, *J* = 8.2 Hz), 6.30 (1H, d, *J* = 5.9 Hz), 2.34 (3H, s), 2.07 (3H, s); ¹³C{¹H} NMR (150 MHz, DMSO-*d*₆) δ (ppm): 171.0, 140.6, 138.1, 137.5, 137.3, 137.1, 136.0, 135.1, 131.4, 130.6, 130.3, 128.8, 127.7, 127.6, 127.2, 125.5, 121.0, 20.8, 20.7; LRMS (EI) *m/z*: 351 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₂₁NO: 351.1623, found: 351.1606; IR (neat): 1688, 1497, 1371, 1300, 1209, 1182, 969, 823, 802 cm⁻¹.

5-(Bis(4-fluorophenyl)methylene)-1-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (2d)




Obtained as yellow crystals in 82% (58.9 mg), recrystallized from DCM/hexane, mp. 153–155 °C.
 ^1H NMR (600 MHz, CDCl_3/TMS) δ (ppm): 7.21 (2H, dd, $J = 8.6, 5.2$ Hz), 7.17 (1H, d, $J = 5.5$ Hz), 7.08 (2H, t, $J = 8.6$ Hz), 7.03 (2H, t, $J = 7.6$ Hz), 6.98 (1H, t, $J = 7.6$ Hz), 6.95–6.93 (2H, m), 6.80 (2H, dd, $J = 8.9, 5.5$ Hz), 6.59 (2H, t, $J = 8.9$ Hz), 6.29 (1H, d, $J = 5.5$ Hz); $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3/TMS) δ (ppm): 171.6, 163.0 (d, $J_{\text{C}-\text{F}} = 249.3$ Hz), 162.1 (d, $J_{\text{C}-\text{F}} = 249.3$ Hz), 139.8, 138.2, 136.4 (d, $J_{\text{C}-\text{F}} = 2.9$ Hz), 135.7, 133.9 (d, $J_{\text{C}-\text{F}} = 2.9$ Hz), 133.2 (d, $J_{\text{C}-\text{F}} = 8.6$ Hz), 132.6 (d, $J_{\text{C}-\text{F}} = 8.6$ Hz), 128.2, 128.1, 127.1, 126.3, 122.1, 115.3 (d, $J_{\text{C}-\text{F}} = 21.5$ Hz), 114.4 (d, $J_{\text{C}-\text{F}} = 22.9$ Hz); ^{19}F NMR (565 MHz, CDCl_3) δ (ppm): -111.7, -111.9; LRMS (EI) m/z : 359 (M^+); HRMS (EI-TOF) Calcd. for $\text{C}_{23}\text{H}_{15}\text{F}_2\text{NO}$: 359.1122, found: 359.1110; IR (neat): 3039, 1688, 1594, 1505, 1497, 1366, 1305, 1231, 1156, 1101, 969, 844 cm^{-1} .

5-(Bis(4-chlorophenyl)methylene)-1-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (2e)



Obtained as yellow crystals in 70% (54.6 mg), recrystallized from DCM/hexane, mp. 206–208 °C.
 ^1H NMR (600 MHz, CDCl_3/TMS) δ (ppm): 7.36 (2H, d, $J = 8.2$ Hz), 7.18–7.16 (3H, m), 7.05–6.99 (3H, m), 6.93–6.92 (2H, m), 6.86 (2H, d, $J = 8.3$ Hz), 6.74 (2H, d, $J = 8.9$ Hz), 6.31 (1H, d, $J = 5.5$ Hz); $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3/TMS) δ (ppm): 171.5, 139.6, 138.7, 138.5, 136.0, 135.5, 134.9, 133.9, 132.7, 132.0, 128.5, 128.2, 127.6, 127.5, 127.1, 126.3, 122.4; LRMS (EI) m/z : 391 (M^+); HRMS (EI-TOF) Calcd. for $\text{C}_{23}\text{H}_{15}^{35}\text{Cl}_2\text{NO}$: 391.0531, found: 391.0503; IR (neat): 3063, 1689, 1595, 1498, 1489, 1216, 1087, 1011, 806 cm^{-1} .


5-(Bis(4-(trifluoromethyl)phenyl)methylene)-1-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (2f)



Obtained as yellow crystals in 63% (58.3 mg), recrystallized from DCM/hexane, mp. 168–170 °C.
 ^1H NMR (600 MHz, CDCl_3/TMS) δ (ppm): 7.66 (2H, d, $J = 8.2$ Hz), 7.37 (2H, d, $J = 8.2$ Hz), 7.21 (1H, d, $J = 6.2$ Hz), 7.14 (2H, d, $J = 8.2$ Hz), 7.02–6.95 (3H, m), 6.93–6.90 (4H, m), 6.37 (1H, d, $J = 5.5$ Hz); $^{13}\text{C}\{\text{H}, \text{F}\}$ NMR (150 MHz, CDCl_3/TMS) δ (ppm): 171.3, 143.4, 140.9, 140.0, 139.4, 135.3, 131.8, 130.9, 130.7, 129.8, 128.3, 127.3, 126.7, 126.4, 125.4, 124.3, 123.9,


123.6, 123.4; ^{19}F NMR (565 MHz, CDCl_3) δ (ppm): -62.1, -62.5; LRMS (EI) m/z : 459 (M^+); HRMS (EI-TOF) Calcd. for $\text{C}_{25}\text{H}_{15}\text{F}_6\text{NO}$: 459.1058, found: 459.1048; IR (neat): 1696, 1612, 1322, 1155, 1121, 1065, 810 cm^{-1} .

1-Phenyl-5-(9*H*-xanthen-9-ylidene)-1,5-dihydro-2*H*-pyrrol-2-one (2g)




Obtained as yellow crystals in 25% (16.4 mg), recrystallized from DCM/hexane, mp. 180–183 °C. ^1H NMR (600 MHz, CDCl_3/TMS) δ (ppm): 8.02 (1H, d, J = 6.0 Hz), 7.62 (1H, dd, J = 7.5, 1.5 Hz), 7.40–7.37 (1H, m), 7.30–7.25 (2H, m), 7.07–7.02 (4H, m), 6.99 (1H, td, J = 7.7, 1.5 Hz), 6.92 (2H, dd, J = 8.0, 1.5 Hz), 6.70 (1H, dd, J = 7.5, 1.5 Hz), 6.40 (1H, d, J = 6.0 Hz), 6.38–6.35 (1H, m); $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3/TMS) δ (ppm): 171.7, 154.2, 153.2, 138.8, 136.5, 134.4, 128.9, 128.7, 128.6, 128.1, 127.5, 126.6, 126.3, 124.2, 123.8, 122.5, 122.0, 121.6, 116.9, 116.3, 115.2; LRMS (EI) m/z : 337 (M^+); HRMS (EI-TOF) Calcd. for $\text{C}_{23}\text{H}_{15}\text{NO}_2$: 337.1103, found: 337.1096; IR (neat): 1684, 1593, 1495, 1447, 1199, 966, 872 cm^{-1} .

5-(5*H*-Dibenzo[*a,d*][7]annulen-5-ylidene)-1-phenyl-1,5-dihydro-2*H*-pyrrol-2-one (2h)




Obtained as yellow crystals in 78% (54.0 mg), recrystallized from DCM/hexane, mp. 235–236 °C. ^1H NMR (600 MHz, CDCl_3/TMS) δ (ppm): 7.40–7.38 (1H, m), 7.35–7.32 (3H, m), 7.28–7.18 (3H, m), 7.08 (1H, d, J = 8.3 Hz), 6.99–6.89 (4H, m), 6.70–6.65 (3H, m), 6.29–6.24 (2H, m); $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3/TMS) δ (ppm): 171.3, 138.4, 136.8, 136.3, 135.7, 135.3, 134.8, 133.5, 131.2, 130.9, 129.3, 128.5, 128.1, 128.0, 127.8, 127.54, 127.49, 127.4, 127.3, 126.9, 126.6, 126.3, 122.6; LRMS (EI) m/z : 347 (M^+); HRMS (EI-TOF) Calcd. for $\text{C}_{25}\text{H}_{17}\text{NO}$: 347.1310, found: 347.1286; IR (neat): 1690, 1496, 1371, 1210, 1167, 786 cm^{-1} .

5-(Diphenylmethylene)-1-(4-methoxyphenyl)-1,5-dihydro-2*H*-pyrrol-2-one (2i)




Obtained as yellow crystals in 77% (54.1 mg), recrystallized from DCM/hexane, mp. 133–134 °C.
¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.37–7.35 (3H, m), 7.23 (2H, dd, *J* = 7.9, 1.7 Hz), 7.18 (1H, d, *J* = 6.2 Hz), 6.99–6.96 (1H, m), 6.91 (2H, t, *J* = 7.6 Hz), 6.86–6.82 (4H, m), 6.53–6.51 (2H, m), 6.27 (1H, d, *J* = 6.2 Hz), 3.66 (3H, s); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 172.0, 157.6, 140.6, 139.9, 138.3, 137.9, 131.6, 130.9, 130.6, 128.8, 128.33, 128.28, 128.0, 127.6, 127.2, 121.7, 113.4, 55.3; LRMS (EI) *m/z*: 353 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₁₉NO₂: 353.1416, found: 353.1410; IR (neat): 3052, 1690, 1613, 1512, 1443, 1248, 1159, 1026, 830, 806 cm⁻¹.

5-(Diphenylmethylene)-1-(*p*-tolyl)-1,5-dihydro-2*H*-pyrrol-2-one (2j)




Obtained as yellow crystals in 81% (54.4 mg), recrystallized from DCM/hexane, mp. 103–105 °C.
¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.37–7.35 (3H, m), 7.24 (2H, dd, *J* = 7.9, 1.7 Hz), 7.18 (1H, d, *J* = 6.2 Hz), 6.95 (1H, t, *J* = 7.5 Hz), 6.88 (2H, t, *J* = 7.5 Hz), 6.83–6.81 (4H, m), 6.77 (2H, d, *J* = 8.2 Hz), 6.26 (1H, d, *J* = 6.2 Hz), 2.14 (3H, s); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.9, 140.7, 140.0, 138.3, 138.0, 135.7, 133.2, 131.6, 130.9, 130.7, 128.5, 128.4, 128.0, 127.4, 127.1, 127.0, 121.8, 20.8; LRMS (EI) *m/z*: 337 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₁₉NO: 337.1467, found: 337.1441; IR (neat): 3030, 1690, 1593, 1515, 1489, 1446, 1374, 1218, 1162, 971, 824 cm⁻¹.

5-(Diphenylmethylene)-1-(4-isopropylphenyl)-1,5-dihydro-2*H*-pyrrol-2-one (2k)




Obtained as orange crystals in 81% (58.9 mg), recrystallized from DCM/hexane, mp. 121–124 °C.
¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.37–7.34 (3H, m), 7.25–7.23 (2H, m), 7.19 (1H, d, *J* = 5.5 Hz), 6.91 (1H, t, *J* = 7.2 Hz), 6.86–6.78 (8H, m), 6.27 (1H, d, *J* = 6.2 Hz), 2.69 (1H, sep, *J* = 6.9 Hz), 1.09 (6H, d, *J* = 6.9 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.8, 146.7, 140.7, 139.9, 138.2, 137.9, 133.3, 131.6, 130.8, 130.7, 128.3, 128.0, 127.5, 127.1, 127.0, 125.9, 121.7, 33.6, 23.8; LRMS (EI) *m/z*: 365 (M⁺); HRMS (EI-TOF) Calcd. for C₂₆H₂₃NO: 365.1780, found: 365.1752; IR (neat): 2958, 2863, 1692, 1371, 1155, 805 cm⁻¹.

5-(Diphenylmethylene)-1-(4-fluorophenyl)-1,5-dihydro-2*H*-pyrrol-2-one (2l)




Obtained as yellow crystals in 78% (53.3 mg), recrystallized from DCM/hexane, mp. 153–155 °C.
¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.39–7.36 (3H, m), 7.25–7.21 (3H, m), 7.01 (1H, t, J = 7.2 Hz), 6.94–6.90 (4H, m), 6.83 (2H, d, J = 6.9 Hz), 6.68 (2H, t, J = 8.6 Hz), 6.27 (1H, d, J = 6.2 Hz); ¹³C{¹H, ¹⁹F} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.9, 160.6, 140.4, 140.3, 138.1, 137.9, 131.9, 131.7, 131.03, 130.95, 128.8, 128.6, 128.2, 128.0, 127.4, 121.7, 114.8; ¹⁹F NMR (565 MHz, CDCl₃) δ (ppm): -115.4; LRMS (EI) *m/z*: 341 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₆FNO: 341.1216, found: 341.1239; IR (neat): 1693, 1600, 1506, 1490, 1382, 1216, 974, 838, 808, 738 cm⁻¹.

1-(4-Chlorophenyl)-5-(diphenylmethylene)-1,5-dihydro-2*H*-pyrrol-2-one (2m)



Obtained as yellow crystals in 88% (63.2 mg), recrystallized from DCM/hexane, mp. 128–130 °C.
¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.39–7.36 (3H, m), 7.25–7.22 (3H, m), 7.03 (1H, t, J = 7.2 Hz), 6.95–6.92 (4H, m), 6.89–6.87 (2H, m), 6.83 (2H, d, J = 6.9 Hz), 6.27 (1H, d, J = 6.2 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.5, 140.4, 140.2, 137.8, 137.7, 134.5, 131.62, 131.57, 131.2, 130.9, 128.6, 128.2, 128.1, 127.99, 127.97, 127.4, 121.6; LRMS (EI) *m/z*: 357 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₆³⁵ClNO: 357.0920, found: 357.0910; IR (neat): 1688, 1593, 1554, 1493, 1446, 1374, 1203, 1089, 971, 833, 798 cm⁻¹.


1-(4-Bromophenyl)-5-(diphenylmethylene)-1,5-dihydro-2*H*-pyrrol-2-one (2n)



Obtained as yellow crystals in 89% (71.4 mg), recrystallized from DCM/hexane, mp. 149–151 °C.
¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.39–7.36 (3H, m), 7.25–7.22 (3H, m), 7.10 (2H, d, J = 8.2 Hz), 7.04 (1H, t, J = 7.6 Hz), 6.94 (2H, t, J = 7.9 Hz), 6.83–6.81 (4H, m), 6.27 (1H, d, J = 5.5 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.5, 140.5, 140.2, 137.8, 137.6,

135.0, 131.6, 131.2, 130.93, 130.89, 128.61, 128.58, 128.1, 128.0, 127.4, 121.7, 119.5; LRMS (EI) *m/z*: 401 (M^+); HRMS (EI-TOF) Calcd. for $C_{23}H_{16}^{79}\text{BrNO}$: 401.0415, found: 401.0427; IR (neat): 3068, 1684, 1489, 1162, 1068, 1015, 831, 798 cm^{-1} .


5-(Diphenylmethylene)-1-(4-(trifluoromethyl)phenyl)-1,5-dihydro-2*H*-pyrrol-2-one (2o)



Obtained as colorless needles in 46% (35.8 mg), recrystallized from DCM/hexane, mp. 136–137 °C.

^1H NMR (600 MHz, CDCl_3/TMS) δ (ppm): 7.41–7.37 (3H, m), 7.27–7.26 (3H, m), 7.23 (2H, d, J = 8.9 Hz), 7.06 (2H, d, J = 8.2 Hz), 6.97 (1H, t, J = 7.2 Hz), 6.90 (2H, t, J = 7.6 Hz), 6.82 (2H, d, J = 7.6 Hz), 6.30 (1H, d, J = 5.5 Hz); $^{13}\text{C}\{^1\text{H}, ^{19}\text{F}\}$ NMR (150 MHz, CDCl_3/TMS) δ (ppm): 171.3, 140.8, 140.1, 139.1, 137.8, 137.5, 131.7, 131.5, 130.8, 128.8, 128.24, 128.19, 127.9, 127.5, 127.2, 124.9, 123.8, 121.7; ^{19}F NMR (565 MHz, CDCl_3) δ (ppm): -62.1; LRMS (EI) *m/z*: 391 (M^+); HRMS (EI-TOF) Calcd. for $C_{24}H_{16}F_3NO$ (M^+): 391.1184, found: 391.1174; IR (neat): 1691, 1379, 1322, 1112, 1063, 975, 853, 800 cm^{-1} .


4-(2-(Diphenylmethylene)-5-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)benzonitrile (2p)



Obtained as yellow crystals in 73% (51.0 mg), recrystallized from DCM/hexane, mp. 178–179 °C.

^1H NMR (600 MHz, CDCl_3/TMS) δ (ppm): 7.43–7.38 (3H, m), 7.29–7.25 (5H, m), 7.09–7.08 (2H, m), 7.03 (1H, t, J = 7.2 Hz), 6.94 (2H, t, J = 7.9 Hz), 6.86–6.84 (2H, m), 6.29 (1H, d, J = 6.2 Hz); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3/TMS) δ (ppm): 171.0, 141.2, 140.0, 139.8, 137.8, 137.0, 131.8, 131.7, 131.6, 130.9, 128.9, 128.5, 128.3, 127.6, 127.2, 121.5, 118.5, 109.0; LRMS (EI) *m/z*: 348 (M^+); HRMS (EI-TOF) Calcd. for $C_{24}H_{16}N_2O$: 348.1263, found: 348.1263; IR (neat): 2226, 1690, 1600, 1506, 1367, 1207, 1159, 970, 845, 799 cm^{-1} .


Methyl 4-(2-(diphenylmethylene)-5-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)benzoate (2q)



Obtained as colorless needles in 78% (58.9 mg), recrystallized from DCM/hexane, mp. 193–195 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.67 (2H, d, *J* = 8.2 Hz), 7.41–7.38 (3H, m), 7.27–7.25 (3H, m), 7.04 (2H, d, *J* = 8.2 Hz), 6.94 (1H, t, *J* = 7.2 Hz), 6.90 (2H, t, *J* = 7.6 Hz), 6.85 (2H, d, *J* = 6.8 Hz), 6.28 (1H, d, *J* = 6.2 Hz), 3.84 (3H, s); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.4, 166.4, 140.8, 140.2, 140.1, 137.9, 137.5, 131.65, 131.58, 131.57, 130.9, 129.3, 128.7, 128.2, 127.5, 127.1, 126.5, 121.6, 52.0; LRMS (EI) *m/z*: 381 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₁₉NO₃: 381.1365, found: 381.1341; IR (neat): 3062, 1722, 1696, 1601, 1507, 1437, 1361, 1275, 1167, 1102, 1072, 969, 863, 802 cm⁻¹.

1-(3-Bromophenyl)-5-(diphenylmethylene)-1,5-dihydro-2*H*-pyrrol-2-one (2r)



Obtained as yellow needles in 85% (68.2 mg), recrystallized from DCM/hexane, mp. 143–145 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.39–7.36 (3H, m), 7.25–7.23 (3H, m), 7.04 (1H, d, *J* = 8.2 Hz), 7.01–6.96 (5H, m), 6.89 (1H, t, *J* = 7.9 Hz), 6.86 (2H, d, *J* = 6.8 Hz), 6.27 (1H, d, *J* = 5.5 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 171.4, 140.5, 140.2, 137.8, 137.5, 136.9, 131.6, 131.3, 130.6, 130.2, 129.1, 128.9, 128.6, 128.14, 128.10, 127.4, 125.8, 121.6, 121.3; LRMS (EI) *m/z*: 401 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₆⁷⁹BrNO (M⁺): 401.0415, found: 401.0438; IR (neat): 1690, 1587, 1476, 1364, 1201, 1152, 980, 802 cm⁻¹.

5. General procedure for the synthesis of 5-alkylidene-pyrrolidin-2-ones

In a glove box, an amide **1** (0.20 mmol), CuBr (2.8 mg, 0.020 mmol), AgBF₄ (3.8 mg, 0.020 mmol), *tert*-butylpyridine (7.4 μL, 0.050 mmol), MnO₂ (52.2 mg, 0.60 mmol), and 1,2-dichloroethane (1.5 mL) were added to a sealed tube. The mixture was stirred at 120 °C for 24 h. After the reaction, the mixture was filtered through Celite and a SiO₂ pad with AcOEt and then the solvent was removed under a reduced pressure. The residue was purified by SiO₂ column chromatography.

Table S2. Copper optimization for the synthesis of **3a**.

Entry	Copper salt	2a (%) ^a	3a (%) ^a
1 ^{b,c}	CuF ₂	5	89
2 ^b	CuF ₂	2	84
3	CuF ₂	0	30
4	Cu(acac) ₂	0	28
5	Cu(BF ₄) ₂ ·6H ₂ O	0	49
6	Cu(OAc) ₂	0	35
7	CuOAc	0	31
8	CuCl	0	23
9	[(MeCN) ₄ Cu]BF ₄	0	28
10	[(MeCN) ₄ Cu]PF ₆	0	36


^a Determined by ¹H-NMR using 1,1,2-trichloroethane as an internal standard. ^b 10 mol% of CuF₂ and 1.0 equiv of 4-*tert*-butylpyridine were used. ^c 4.0 equiv of MnO₂ was used.

Table S3. Optimization of copper and silver salts for the synthesis of **3a**.

Entry	Copper salt	Silver salt	2a (%) ^a	3a (%) ^a
1	Cu(BF ₄) ₂ ·6H ₂ O	None	0	49
2	CuBr	AgBF ₄	2	69
3	CuBr	AgSbF ₆	1	56
4	CuBr	AgNTf ₂	3	30
5	None	AgBF ₄	0	1
6 ^b	CuBr	AgBF ₄	3	55

^a Determined by ¹H-NMR using 1,1,2-trichloroethane as an internal standard.


^b 10 mol% of copper and silver salts were used.

Table S4. Detailed reaction conditions for the synthesis of **3a**.

Entry	Time (h)	X (mol%)	Y (M)	2a (%) ^a	3a (%) ^a
1	18	15	0.080	3	55
2	24	15	0.080	3	67
3	24	25	0.080	3	74
4	24	35	0.080	1	50
6	24	25	0.067	1	42
7	24	25	0.10	3	69
8	24	25	0.13	5	94 (91)

^a Determined by ¹H-NMR using 1,1,2-trichloroethane as an internal standard. Isolated yield in parentheses.


Scheme S1. Unsuccessful substrates under condition B.



Yields were determined by ¹H-NMR using 1,1,2-trichloroethane as an internal standard.

^a Reaction conditions: **1** (0.20 mmol), CuBr (0.020 mmol), AgBF₄ (0.020 mmol), 4-*tert*-butylpyridine (0.050 mmol), and MnO₂ (0.60 mmol) in 1,2-DCE (1.5 mL) at 120 °C for 24 h.


5-(Diphenylmethylene)-1-phenylpyrrolidin-2-one (3a)



Obtained as colorless plates in 91% (59.0 mg), recrystallized from DCM/hexane, mp. 146–148 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.31–7.29 (2H, m), 7.25–7.22 (1H, m), 7.19–7.18 (2H, m), 7.00–6.96 (4H, m), 6.90–6.88 (1H, m), 6.83–6.81 (3H, m), 6.72–6.71 (2H, m), 2.99–2.97 (2H, m), 2.71–2.68 (2H, m); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.3, 142.1, 139.2, 137.9, 136.1, 130.1, 130.0, 128.2, 127.9, 127.1, 126.7, 126.2, 126.0, 125.9, 120.2, 30.9, 28.3; LRMS (EI) *m/z*: 325 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₉NO: 325.1467, found: 325.1456; IR (neat): 3046, 1723, 1620, 1595, 1495, 1359, 1160, 1027, 773, 751 cm⁻¹.


5-(Bis(4-methoxyphenyl)methylene)-1-phenylpyrrolidin-2-one (3b)



Obtained as yellow crystals in 61% (46.8 mg), recrystallized from DCM/hexane, mp. 164–166 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.09 (2H, d, *J* = 8.9 Hz), 6.99–6.98 (4H, m), 6.91–6.90 (1H, m), 6.84 (2H, d, *J* = 8.9 Hz), 6.61 (2H, d, *J* = 8.9 Hz), 6.36 (2H, d, *J* = 8.9 Hz), 3.80 (3H, s), 3.62 (3H, s), 2.96 (2H, t, *J* = 7.7 Hz), 2.68 (2H, t, *J* = 7.7 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.3, 158.3, 157.7, 136.7, 136.1, 134.6, 132.0, 131.1, 131.0, 127.9, 126.1, 125.9, 119.5, 113.5, 112.6, 55.2, 55.1, 31.1, 28.4; LRMS (EI) *m/z*: 385 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₂₃NO₃: 385.1678, found: 385.1706; IR (neat): 2969, 2835, 1713, 1606, 1508, 1358, 1179, 1027, 829, 761 cm⁻¹.


5-(Di-*p*-tolylmethylene)-1-phenylpyrrolidin-2-one (3c)



Obtained as colorless needles in 99% (69.4 mg, **3c : 2c = 93 : 7**), recrystallized from DCM/hexane, mp. 208–211 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.10 (2H, d, *J* = 8.2 Hz), 7.06 (2H, d, *J* = 8.2 Hz), 6.98–6.95 (4H, m), 6.90–6.87 (1H, m), 6.61 (2H, d, *J* = 8.2 Hz), 6.58 (2H, d, *J* = 8.2 Hz), 2.97 (2H, t, *J* = 7.6 Hz), 2.68 (2H, t, *J* = 7.6 Hz), 2.34 (3H, s), 2.09 (3H, s); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.3, 139.3, 137.3, 136.4, 136.3, 136.2, 135.5, 129.9, 129.8, 128.8, 127.85, 127.76, 126.2, 125.7, 120.2, 31.1, 28.4, 21.1, 20.9; LRMS (EI) *m/z*: 353 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₂₃NO: 353.1780, found: 353.1775; IR (neat): 3019, 2927, 1732, 1636, 1496, 1369, 1228, 1154, 815 cm⁻¹.


5-(Bis(4-fluorophenyl)methylene)-1-phenylpyrrolidin-2-one (3d)



Obtained as colorless crystals in 80% (58.2 mg, **3d** : **2d** = 95 : 5), recrystallized from DCM/hexane, mp. 179–181 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.14–7.12 (2H, m), 7.03–6.94 (7H, m), 6.67–6.64 (2H, m), 6.52 (2H, t, *J* = 8.6 Hz), 2.95 (2H, t, *J* = 7.9 Hz), 2.70 (2H, t, *J* = 7.9 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.2, 161.6 (¹J_{C-F} = 246.4 Hz), 161.0 (¹J_{C-F} = 246.4 Hz), 138.4, 137.8 (⁴J_{C-F} = 4.3 Hz), 135.9, 135.1 (⁴J_{C-F} = 2.9 Hz), 131.55 (³J_{C-F} = 7.2 Hz), 131.48 (³J_{C-F} = 8.6 Hz), 128.1, 126.4, 126.3, 117.8, 115.2 (²J_{C-F} = 21.5 Hz), 114.1 (²J_{C-F} = 21.5 Hz), 30.8, 28.2; ¹⁹F NMR (565 MHz, CDCl₃) δ (ppm): -114.5, -115.2; LRMS (EI) *m/z*: 361 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₇F₂NO: 361.1278, found: 361.1262; IR (neat): 3040, 1736, 1632, 1598, 1505, 1370, 1293, 1153, 831, 758 cm⁻¹.


5-(Bis(4-chlorophenyl)methylene)-1-phenylpyrrolidin-2-one (**3e**)



Obtained as colorless needles in 82% (65.5 mg, **3e** : **2e** = 94 : 6), recrystallized from DCM/hexane, mp. 204–206 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.28 (2H, d, *J* = 8.2 Hz), 7.09 (2H, d, *J* = 8.2 Hz), 7.04–7.01 (2H, m), 6.98 (1H, d, *J* = 6.9 Hz), 6.95 (2H, d, *J* = 7.6 Hz), 6.79 (2H, d, *J* = 8.2 Hz), 6.61 (2H, d, *J* = 8.2 Hz), 2.96 (2H, t, *J* = 7.7 Hz), 2.71 (2H, t, *J* = 7.7 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.1, 140.0, 139.1, 137.3, 135.8, 132.7, 132.0, 131.30, 131.26, 128.5, 128.2, 127.4, 126.5, 126.3, 117.4, 30.7, 28.2; LRMS (EI) *m/z*: 393 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₇³⁵Cl₂NO: 393.0687, found: 393.0671; IR (neat): 3064, 2944, 1732, 1612, 1488, 1355, 1156, 1012, 828, 756 cm⁻¹.

5-(5*H*-Dibenzo[*a,d*][7]annulen-5-ylidene)-1-phenylpyrrolidin-2-one (**3h**)




Obtained as colorless crystals in 66% (46.3 mg), recrystallized from DCM/hexane, mp. 199–200 °C.

¹H-NMR (600 Hz, DMSO-*d*₆) δ (ppm): 7.42–7.36 (3H, m), 7.27–7.24 (1H, m), 7.02–6.89 (6H, m), 6.83–6.56 (5H, m), 3.12–3.08 (1H, m), 2.70–2.64 (1H, m), 2.45–2.41 (1H, m), 2.26–2.21

(1H, m); $^{13}\text{C}\{\text{H}\}$ NMR (150 Hz, DMSO-*d*₆), δ (ppm): 176.3, 138.3, 137.1, 136.8, 136.4, 134.9, 133.8, 131.3, 130.9, 128.9, 128.7, 128.3, 128.1, 127.8, 127.3, 127.2, 127.0, 126.4, 126.3, 125.6, 114.1, 28.7, 24.2; LRMS (EI) *m/z*: 349 (M⁺); HRMS (EI-TOF) Calcd. for C₂₅H₁₉NO: 349.1467, found: 349.1465; IR (neat): 3017, 1717, 1636, 1497, 1370, 1239, 1171, 803, 738 cm⁻¹.


5-(Diphenylmethylene)-1-(4-methoxyphenyl)pyrrolidin-2-one (3i)



Obtained as colorless needles in 76% (54.7 mg, **3i** : **2i** = 93 : 7), recrystallized from DCM/hexane, mp. 158–161 °C.

^1H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.29 (2H, t, *J* = 7.6 Hz), 7.22 (1H, t, *J* = 7.2 Hz), 7.18 (2H, d, *J* = 6.9 Hz), 6.88–6.84 (5H, m), 6.71–6.70 (2H, m), 6.50 (2H, d, *J* = 8.9 Hz), 3.65 (3H, s), 2.96 (2H, t, *J* = 7.9 Hz), 2.67 (2H, t, *J* = 7.9 Hz); $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.6, 157.6, 142.2, 139.1, 138.2, 130.2, 129.9, 129.1, 128.2, 127.5, 127.1, 126.6, 125.9, 119.7, 113.4, 55.4, 30.7, 28.1; LRMS (EI) *m/z*: 355 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₂₁NO₂: 355.1572, found: 355.1549; IR (neat): 3257, 1700, 1636, 1511, 1444, 1242, 1031, 741 cm⁻¹.


5-(Diphenylmethylene)-1-(*p*-tolyl)pyrrolidin-2-one (3j)



Obtained as yellow oil in 92% (62.7 mg, **3j** : **2j** = 93 : 7).

^1H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.30 (2H, t, *J* = 7.5 Hz), 7.22 (1H, tt, *J* = 7.4, 1.5 Hz), 7.19–7.17 (2H, m), 6.85–6.80 (5H, m), 6.76 (2H, d, *J* = 8.1 Hz), 6.71–6.69 (2H, m), 2.98–2.95 (2H, m), 2.69–2.67 (2H, m), 2.13 (3H, s); $^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.5, 142.2, 139.2, 138.1, 135.8, 133.5, 130.2, 130.0, 128.5, 128.2, 127.1, 126.6, 126.2, 125.7, 119.9, 30.8, 28.2, 20.8; LRMS (EI) *m/z*: 339 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₂₁NO: 339.1623, found: 339.1617; IR (neat): 3057, 1718, 1631, 1512, 1364, 1229, 1167, 1030, 816, 751 cm⁻¹.


5-(Diphenylmethylene)-1-(4-isopropylphenyl)pyrrolidin-2-one (3k)



Obtained as colorless oil in 99% (72.5 mg, **3k** : **2k** = 92 : 8).

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.29 (2H, t, *J* = 7.6 Hz), 7.22 (1H, t, *J* = 7.6 Hz), 7.18 (2H, d, *J* = 7.6 Hz), 6.85 (2H, d, *J* = 8.9 Hz), 6.80–6.79 (5H, m), 6.67 (2H, dd, *J* = 6.5, 3.1 Hz), 2.96 (2H, t, *J* = 7.9 Hz), 2.70–2.65 (3H, m), 1.09 (6H, d, *J* = 6.8 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.5, 146.8, 142.2, 139.1, 138.1, 133.6, 130.1, 129.9, 128.2, 127.0, 126.5, 126.3, 126.0, 125.8, 119.7, 33.7, 30.7, 28.1, 23.9; LRMS (EI) *m/z*: 367 (M⁺); HRMS (EI-TOF) Calcd. for C₂₆H₂₅NO: 367.1936, found: 367.1925; IR (neat): 3018, 2959, 1723, 1630, 1512, 1364, 1300, 1229, 1167, 832 cm⁻¹.


5-(Diphenylmethylene)-1-(4-fluorophenyl)pyrrolidin-2-one (3l)



Obtained as colorless needle in 92% (63.4 mg, **3l** : **2l** = 93 : 7), recrystallized from DCM/hexane, mp. 128–130 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.32–7.29 (2H, m), 7.25–7.22 (1H, m), 7.18–7.16 (2H, m), 6.96–6.93 (2H, m), 6.91–6.85 (3H, m), 6.72–6.70 (2H, m), 6.68–6.65 (2H, m), 3.00–2.97 (2H, m), 2.70–2.68 (2H, m); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.4, 160.5 (¹J_{C-F} = 245.0 Hz), 141.9, 139.1, 137.9, 132.1 (⁴J_{C-F} = 2.9 Hz) 130.2, 129.9, 128.2, 128.0 (³J_{C-F} = 8.6 Hz), 127.3, 126.8, 126.2, 120.2, 114.8 (²J_{C-F} = 22.9 Hz), 30.8, 28.2; ¹⁹F NMR (565 MHz, CDCl₃) δ (ppm): -115.1; LRMS (EI) *m/z*: 343 (M⁺); HRMS (EI-TOF) Calcd. For C₂₃H₁₈FN: 343.1372, found: 343.1352; IR (neat): 3058, 1724, 1633, 1604, 1507, 1368, 1299, 1228, 1153, 910, 752 cm⁻¹.


1-(4-Chlorophenyl)-5-(diphenylmethylene)pyrrolidin-2-one (3m)



Obtained as colorless needles in 76% (55.4 mg), recrystallized from DCM/hexane, mp. 165–167 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.31 (2H, t, *J* = 7.6 Hz), 7.25–7.22 (1H, m), 7.18–7.17 (2H, m), 6.94–6.86 (7H, m), 6.72–6.70 (2H, m), 2.98 (2H, t, *J* = 7.9 Hz), 2.69 (2H, t, *J* = 7.9 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.1, 141.7, 139.0, 137.6, 134.6, 131.4, 130.1, 129.9, 128.2, 128.0, 127.42, 127.38, 126.8, 126.2, 120.5, 30.9, 28.2; LRMS (EI) *m/z*: 359 (M⁺); HRMS (EI-TOF) Calcd. for C₂₃H₁₈³⁵ClNO: 359.1077, found: 359.1092; IR (neat): 3076, 2929, 1719, 1636, 1492, 1364, 1300, 1233, 1165, 1088, 833 cm⁻¹.


1-(4-Bromophenyl)-5-(diphenylmethylene)pyrrolidin-2-one (**3n**)



Obtained as colorless needles in 80% (64.7 mg, **3n** : **2n** = 96 : 4), recrystallized from DCM/hexane, mp. 188–189 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.30 (2H, t, *J* = 7.6 Hz), 7.25–7.24 (1H, m), 7.17 (2H, d, *J* = 7.5 Hz), 7.08 (2H, d, *J* = 8.9 Hz), 6.91 (1H, t, *J* = 9.6 Hz), 6.87–6.85 (4H, m), 6.70 (2H, d, *J* = 7.6 Hz), 2.98 (2H, t, *J* = 7.9 Hz), 2.68 (2H, t, *J* = 7.9 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.1, 141.7, 139.0, 137.5, 135.1, 131.0, 130.1, 129.9, 128.2, 127.7, 127.4, 126.8, 126.2, 120.5, 119.4, 30.9, 28.2; LRMS (EI) *m/z*: 403 (M⁺); HRMS (EI-TOF) Calcd. For C₂₃H₁₈⁷⁹BrNO: 403.0572, found: 403.0550; IR (neat): 3074, 1718, 1636, 1488, 1365, 1301, 1235, 1166, 1067, 1012 cm⁻¹.

5-(Diphenylmethylene)-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one (**3o**)




Obtained as yellow crystals in 69% (54.4 mg, **3o** : **2o** = 95 : 5), recrystallized from DCM/hexane, mp. 169–170 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.32 (2H, t, *J* = 7.6 Hz), 7.26–7.18 (5H, m), 7.10 (2H, d, *J* = 8.3 Hz), 6.84–6.83 (3H, m), 6.69 (2H, dd, *J* = 7.6, 1.4 Hz), 3.01 (2H, t, *J* = 7.7 Hz), 2.72 (2H, t, *J* = 7.7 Hz); ¹³C{¹H, ¹⁹F} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.0, 141.5, 139.1, 139.0, 137.2, 130.0, 129.9, 128.2, 127.8, 127.4, 126.9, 126.4, 126.3, 125.0, 123.7, 121.0, 31.0, 28.2; ¹⁹F NMR (565 MHz, CDCl₃) δ (ppm): -62.1; LRMS (EI) *m/z*: 393 (M⁺); HRMS (EI-TOF)

Calcd. For C₂₄H₁₈F₃NO: 393.1340, found: 393.1328; IR (neat): 3060, 1721, 1636, 1592, 1490, 1366, 1324, 1232, 1161, 851, 753 cm⁻¹.


4-(2-(Diphenylmethylene)-5-oxopyrrolidin-1-yl)benzonitrile (3p)



Obtained as colorless crystals in 84% (59.1 mg, **3p : 2p** = 98 : 2), recrystallized from DCM/hexane, mp. 200–201 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.32 (2H, t, *J* = 7.5 Hz), 7.28–7.25 (3H, m), 7.18 (2H, d, *J* = 6.9 Hz), 7.14 (2H, d, *J* = 8.3 Hz), 6.90–6.86 (3H, m), 6.72–6.71 (2H, m), 3.01 (2H, t, *J* = 7.7 Hz), 2.73 (2H, t, *J* = 7.7 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 175.8, 141.2, 140.0, 139.0, 136.73, 136.72, 131.8, 129.9, 128.3, 127.6, 127.1, 126.7, 126.2, 121.8, 118.5, 108.9, 31.2, 28.3; LRMS (EI) *m/z*: 350 (M⁺); HRMS (EI-TOF) Calcd. For C₂₄H₁₈N₂O: 350.1419, found: 350.1396; IR (neat): 3044, 2224, 1721, 1635, 1601, 1506, 1355, 1227, 1162, 844 cm⁻¹.


Methyl 4-(2-(diphenylmethylene)-5-oxopyrrolidin-1-yl)benzoate (3q)



Obtained as colorless crystals in 84% (64.4 mg, **3q : 2q** = 98 : 2), recrystallized from DCM/hexane, mp. 191–192 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.65 (2H, d, *J* = 8.9 Hz), 7.31 (2H, t, *J* = 7.6 Hz), 7.26–7.24 (1H, m), 7.19 (2H, d, *J* = 6.8 Hz), 7.09 (2H, d, *J* = 8.2 Hz), 6.85–6.81 (3H, m), 6.73 (2H, d, *J* = 7.6 Hz), 3.84 (3H, s), 3.00 (2H, t, *J* = 7.9 Hz), 2.71 (2H, t, *J* = 7.9 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.0, 166.4, 141.6, 140.2, 139.0, 137.3, 130.0, 129.3, 128.2, 127.4, 127.1, 126.9, 126.40, 126.39, 125.6, 121.4, 52.0, 31.2, 28.4; LRMS (EI) *m/z*: 383 (M⁺); HRMS (EI-TOF) Calcd. For C₂₅H₂₁NO₃: 383.1521, found: 383.1511; IR (neat): 3056, 2952, 1723, 1710, 1630, 1439, 1361, 1278, 1227, 855, 765 cm⁻¹.


1-(3-Bromophenyl)-5-(diphenylmethylene)pyrrolidin-2-one (3r)



Obtained as yellow crystals in 78% (63.2 mg, **3r** : **2r** = 95 : 5), recrystallized from DCM/hexane, mp. 138–140 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.31 (2H, t, *J* = 7.5 Hz), 7.25–7.23 (1H, m), 7.18 (2H, d, *J* = 7.5 Hz), 7.06 (1H, s), 7.01 (2H, d, *J* = 8.0 Hz), 6.92–6.85 (4H, m), 6.74 (2H, d, *J* = 6.5 Hz), 2.99 (2H, t, *J* = 7.8 Hz), 2.69 (2H, t, *J* = 7.8 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 176.0, 141.6, 139.0, 137.4, 137.1, 129.93, 129.91, 129.4, 129.1, 129.0, 128.2, 127.4, 126.8, 126.3, 124.9, 121.4, 120.8, 30.9, 28.2; LRMS (EI) *m/z*: 403 (M⁺); HRMS (EI-TOF) Calcd. For C₂₃H₁₈⁷⁹BrNO: 403.0572, found: 403.0580; IR (neat): 3057, 1724, 1631, 1590, 1571, 1476, 1352, 1220, 1155, 764 cm⁻¹.

1-(Benzo[d]thiazol-2-yl)-5-(diphenylmethylene)pyrrolidin-2-one (3s)




Obtained as colorless needles in 38% (29.9 mg), recrystallized from DCM/hexane, mp. 192–193 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.64 (1H, d, *J* = 8.2 Hz), 7.45 (1H, d, *J* = 8.3 Hz), 7.34–7.23 (6H, m), 7.19 (1H, t, *J* = 7.2 Hz), 6.93 (2H, d, *J* = 7.6 Hz), 6.82 (2H, t, *J* = 7.9 Hz), 6.64 (1H, t, *J* = 7.5 Hz), 3.08 (2H, t, *J* = 7.5 Hz), 2.79 (2H, t, *J* = 7.5 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 175.1, 154.2, 148.3, 140.9, 140.3, 134.8, 133.1, 130.2, 129.0, 128.1, 127.3, 127.2, 126.4, 125.7, 125.5, 124.3, 122.1, 120.8, 31.5, 28.5; LRMS (EI) *m/z*: 382 (M⁺); HRMS (EI-TOF) Calcd. for C₂₄H₁₈N₂OS (M⁺): 382.1140, found: 382.1167; IR (neat): 3048, 2914, 1723, 1635, 1512, 1279, 1234, 1168, 749 cm⁻¹.

6. Mechanistic experiment

5-(Chlorodiphenylmethyl)-1-phenylpyrrolidin-2-one (4a)



In a glove box, **1a** (65.6 mg, 0.20 mmol), CuF₂ (2.0 mg, 0.020 mmol), 4-*tert*-butylpyridine (29.3 μL, 0.020 mmol), *t*BuOO*t*Bu (147.0 μL, 0.80 mmol), and 1,2-dichloroethane (2.5 mL) were added

to a sealed tube. The mixture was stirred at 120 °C for 3 h. The reaction was diluted with water (10 mL) and extracted with chloroform (10 mL × 3). The organic layers were washed with brine (10 mL) and dried over MgSO₄ and the solvent was removed under a reduced pressure. The residue was purified by SiO₂ column chromatography.

Obtained as colorless needles in 50% (36.2 mg), recrystallized from DCM/hexane, mp. 156–157 °C.

¹H NMR (600 MHz, CDCl₃/TMS) δ (ppm): 7.43 (2H, d, *J* = 6.9 Hz), 7.31–7.23 (5H, m), 7.09 (4H, d, *J* = 4.8 Hz), 7.05–7.01 (3H, m), 7.00–6.96 (1H, m), 5.62 (1H, d, *J* = 8.3 Hz), 2.62–2.54 (1H, m), 2.34–2.28 (2H, m), 2.24–2.15 (1H, m); ¹³C{¹H} NMR (150 MHz, CDCl₃/TMS) δ (ppm): 175.9, 142.6, 141.2, 138.7, 128.3, 128.2, 128.1, 127.9, 127.8, 127.5, 125.8, 125.77, 125.76, 82.5, 67.5, 30.5, 24.2; LRMS (FAB) *m/z*: 362 (M+H)⁺; HRMS (FAB-EB) Calcd. For C₂₃H₂₁³⁵ClNO (M+H)⁺: 362.1312, found: 362.1324; IR (neat): 3067, 1689, 1599, 1499, 1404, 1291, 1039, 749 cm⁻¹.

7. X-Ray crystallographic data for **4a**

Single crystals suitable for X-ray crystallography were obtained by vapor diffusion of hexane into a AcOEt solution of **4a**. A suitable crystal was selected and mounted on a Bruker D8 goniometer diffractometer. The crystal was kept at 93(1) K during data collection. Using Olex2¹⁾, the structure was solved with the olex2.solve²⁾ structure solution program using Charge Flipping and refined with the SHELXL³⁾ refinement package using Least Squares minimization.

Crystallographic data of **4a** has been deposited with Cambridge Crystallographic Data Center, Deposition no. CCDC 2284469. The data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

1) Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009), *J. Appl. Cryst.* 42, 339–341.

2) Bourhis, L. J., Dolomanov, O. V., Gildea, R. J., Howard, J. A. K., Puschmann, H. (2015). *Acta Cryst. A*71, 59–75.

3) Sheldrick, G. M. (2015). *Acta Cryst. C*71, 3–8.

Table S5. Crystal data and structure refinements for **4a**.

Empirical formula	C ₂₃ H ₂₀ ClNO
Formula weight	361.85
Temperature/K	90(1)
Crystal system	triclinic
Space group	<i>P</i> -1
a/Å	12.583(3)
b/Å	13.818(3)
c/Å	22.012(5)
α /°	106.734(9)
β /°	90.764(8)
γ /°	90.173(8)
Volume/Å ³	3664.8(15)
Z	8
ρ calcg/cm ³	1.312
μ /mm ⁻¹	0.220
F(000)	1520.0
Crystal size/mm ³	0.58 × 0.21 × 0.15
Radiation	MoKα ($\lambda = 0.71073$)
2Θ range for data collection/°	3.864 to 55.906
Index ranges	-16 ≤ h ≤ 16, -18 ≤ k ≤ 17, 0 ≤ l ≤ 29
Reflections collected	17725
Independent reflections	17725 [$R_{\text{sigma}} = 0.0753$]
Data/restraints/parameters	17725/0/938
Goodness-of-fit on F ²	1.029
Final <i>R</i> indexes [$I >= 2\sigma (I)$]	$R_1 = 0.0599$, wR ₂ = 0.1445
Final <i>R</i> indexes [all data]	$R_1 = 0.0883$, wR ₂ = 0.1607
Largest diff. peak/hole / e Å ⁻³	0.61/-0.66







Figure S1. ORTEP diagram of **4a** with thermal ellipsoids drawn at 50% probability level (CCDC No. 2284469). Color code of atoms: hydrogen, white; carbon, gray; chlorine, green; nitrogen, blue; oxygen, red.

8. ^1H -, ^{13}C -, and ^{19}F -NMR spectra


^1H -NMR spectrum of **1a** (CDCl_3 , 400 MHz)




^{13}C -NMR spectrum of **1a** (CDCl_3 , 100 MHz)




IR spectrum of **1a**




HRMS spectrum of **1a**




¹H-NMR spectrum of **1b** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1b** (CDCl₃, 150 MHz)




IR spectrum of **1b**




HRMS spectrum of **1b**




¹H-NMR spectrum of **1c** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1c** (CDCl₃, 150 MHz)




IR spectrum of **1c**




HRMS spectrum of **1c**




¹H-NMR spectrum of **1d** (CDCl₃, 400 MHz)




¹³C-NMR spectrum of **1d** (CDCl₃, 100 MHz)




¹⁹F-NMR spectrum of **1d** (CDCl_3 , 565 MHz)




IR spectrum of **1d**




HRMS spectrum of **1d**




¹H-NMR spectrum of **1e** (DMSO-*d*₆, 600 MHz)




¹³C-NMR spectrum of **1e** (DMSO-*d*₆, 150 MHz)




IR spectrum of **1e**




HRMS spectrum of **1e**




¹H-NMR spectrum of **1f** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1f** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **1f** (CDCl₃, 565 MHz)




IR spectrum of **1f**




HRMS spectrum of **1f**




¹H-NMR spectrum of **1g** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1g** (CDCl₃, 150 MHz)





IR spectrum of **1g**




HRMS spectrum of **1g**




¹H-NMR spectrum of **1h** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1h** (CDCl₃, 150 MHz)





IR spectrum of **1h**




HRMS spectrum of **1h**




¹H-NMR spectrum of **1i** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1i** (CDCl₃, 150 MHz)





IR spectrum of **1i**




HRMS spectrum of **1i**




¹H-NMR spectrum of **1j** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1j** (CDCl₃, 150 MHz)





IR spectrum of **1j**




HRMS spectrum of **1j**




¹H-NMR spectrum of **1k** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1k** (CDCl₃, 150 MHz)




IR spectrum of **1k**




HRMS spectrum of **1k**





¹H-NMR spectrum of **1l** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1l** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **1l** (CDCl₃, 565 MHz)





IR spectrum of **1I**




HRMS spectrum of **1I**




¹H-NMR spectrum of **1m** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1m** (CDCl₃, 150 MHz)





IR spectrum of **1m**




HRMS spectrum of **1m**




¹H-NMR spectrum of **1n** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1n** (CDCl₃, 150 MHz)





IR spectrum of **1n**





HRMS spectrum of **1n**




¹H-NMR spectrum of **1o** (CDCl₃, 600 MHz)




¹⁹F-NMR spectrum of **1o** (CDCl_3 , 565 MHz)




IR spectrum of **1o**




HRMS spectrum of **1o**




¹H-NMR spectrum of **1p** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1p** (CDCl₃, 150 MHz)





IR spectrum of **1p**




HRMS spectrum of **1p**




¹H-NMR spectrum of **1q** (DMSO-*d*₆, 600 MHz)




¹³C-NMR spectrum of **1q** (DMSO-*d*₆, 150 MHz)





IR spectrum of **1q**




HRMS spectrum of **1q**




¹H-NMR spectrum of **1r** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **1r** (CDCl₃, 150 MHz)





IR spectrum of **1r**




HRMS spectrum of **1r**




¹H-NMR spectrum of **1s** (CDCl₃, 600 MHz)




IR spectrum of **1s**




HRMS spectrum of **1s**




¹H-NMR spectrum of **2a** (CDCl₃, 400 MHz)




¹³C-NMR spectrum of **2a** (CDCl₃, 150 MHz)




IR spectrum of **2a**




HRMS spectrum of **2a**




¹H-NMR spectrum of **2b** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2b** (CDCl₃, 150 MHz)




IR spectrum of **2b**




HRMS spectrum of **2b**




¹H-NMR spectrum of **2c** (DMSO-*d*₆, 600 MHz)




¹³C-NMR spectrum of **2c** (DMSO-*d*₆, 150 MHz)




IR spectrum of **2c**




HRMS spectrum of **2c**




¹H-NMR spectrum of **2d** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2d** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **2d** (CDCl_3 , 565 MHz)




IR spectrum of **2d**




HRMS spectrum of **2d**




¹H-NMR spectrum of **2e** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2e** (CDCl₃, 150 MHz)





IR spectrum of **2e**




HRMS spectrum of **2e**





¹H-NMR spectrum of **2f** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2f** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **2f** (CDCl₃, 565 MHz)




IR spectrum of **2f**




HRMS spectrum of **2f**




¹H-NMR spectrum of **2g** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2g** (CDCl₃, 150 MHz)





IR spectrum of **2g**




HRMS spectrum of **2g**




¹H-NMR spectrum of **2h** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2h** (CDCl₃, 150 MHz)




IR spectrum of **2h**




HRMS spectrum of **2h**




¹H-NMR spectrum of **2i** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2i** (CDCl₃, 150 MHz)




IR spectrum of **2i**




HRMS spectrum of **2i**




¹H-NMR spectrum of **2j** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2j** (CDCl₃, 150 MHz)




IR spectrum of **2j**




HRMS spectrum of **2j**




¹H-NMR spectrum of **2k** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2k** (CDCl₃, 150 MHz)





IR spectrum of **2k**




HRMS spectrum of **2k**





¹H-NMR spectrum of **2I** (CDCl_3 , 600 MHz)




¹³C-NMR spectrum of **2l** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **2l** (CDCl₃, 565 MHz)




IR spectrum of **2I**




HRMS spectrum of **2I**




¹H-NMR spectrum of **2m** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2m** (CDCl₃, 150 MHz)





IR spectrum of **2m**




HRMS spectrum of **2m**




¹H-NMR spectrum of **2n** (CDCl₃, 600 MHz)




IR spectrum of **2n**




HRMS spectrum of **2n**





¹H-NMR spectrum of **2o** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2o** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **2o** (CDCl₃, 565 MHz)




IR spectrum of **2o**




HRMS spectrum of **2o**




¹H-NMR spectrum of **2p** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2p** (CDCl₃, 150 MHz)




IR spectrum of **2p**




HRMS spectrum of **2p**




¹H-NMR spectrum of **2q** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2q** (CDCl₃, 150 MHz)




IR spectrum of **2q**




HRMS spectrum of **2q**




¹H-NMR spectrum of **2r** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **2r** (CDCl₃, 150 MHz)




IR spectrum of **2r**




HRMS spectrum of **2r**




¹H-NMR spectrum of **3a** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3a** (CDCl₃, 150 MHz)




IR spectrum of **3a**




HRMS spectrum of **3a**




¹H-NMR spectrum of **3b** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3b** (CDCl₃, 150 MHz)




IR spectrum of **3b**





HRMS spectrum of **3b**




¹H-NMR spectrum of **3c** (**3c** : **2c** = 93 : 7, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3c** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3c** (CDCl₃, 150 MHz)




IR spectrum of **3c**




HRMS spectrum of **3c**




¹H-NMR spectrum of **3d** (**3d** : **2d** = 95 : 5, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3d** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3d** (CDCl_3 , 150 MHz)




¹⁹F-NMR spectrum of **3d** (CDCl_3 , 565 MHz)




IR spectrum of **3d**




HRMS spectrum of **3d**




¹H-NMR spectrum of **3e** (**3e** : **2e** = 94 : 6, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3e** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3e** (CDCl₃, 150 MHz)




IR spectrum of **3e**




HRMS spectrum of **3e**




¹H-NMR spectrum of **3h** (DMSO-*d*₆, 600 MHz)




¹³C-NMR spectrum of **3h** (DMSO-*d*₆, 150 MHz)




IR spectrum of **3h**




HRMS spectrum of **3h**




¹H-NMR spectrum of **3i** (**3i** : **2i** = 93 : 7, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3i** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3i** (CDCl₃, 150 MHz)




IR spectrum of **3i**




HRMS spectrum of **3i**




¹H-NMR spectrum of **3j** (**3j** : **2j** = 93 : 7, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3j** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3j** (CDCl₃, 150 MHz)





IR spectrum of **3j**




HRMS spectrum of **3j**




¹H-NMR spectrum of **3k** (**3k** : **2k** = 92 : 8, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3k** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3k** (CDCl₃, 150 MHz)




IR spectrum of **3k**




HRMS spectrum of **3k**




¹H-NMR spectrum of **3l** (**3l** : **2l** = 93 : 7, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3l** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3l** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **3l** (CDCl₃, 565 MHz)





IR spectrum of **3I**




HRMS spectrum of **3I**




¹H-NMR spectrum of **3m** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3m** (CDCl₃, 150 MHz)




IR spectrum of **3m**




HRMS spectrum of **3m**




¹H-NMR spectrum of **3n** (**3n** : **2n** = 96 : 4, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3n** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3n** (CDCl₃, 150 MHz)




IR spectrum of **3n**




HRMS spectrum of **3n**




¹H-NMR spectrum of **3o** (**3o** : **2o** = 95 : 5, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3o** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3o** (CDCl₃, 150 MHz)




¹⁹F-NMR spectrum of **3o** (CDCl₃, 565 MHz)





IR spectrum of **3o**




HRMS spectrum of **3o**




¹H-NMR spectrum of **3p** (**3p** : **2p** = 98 : 2, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3p** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3p** (CDCl₃, 150 MHz)





IR spectrum of **3p**




HRMS spectrum of **3p**




¹H-NMR spectrum of **3q** (**3q** : **2q** = 98 : 2, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3q** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3q** (CDCl₃, 150 MHz)





IR spectrum of **3q**





HRMS spectrum of **3q**




¹H-NMR spectrum of **3r** (**3r** : **2r** = 95 : 5, CDCl₃, 400 MHz)




¹H-NMR spectrum of **3r** (CDCl₃, 600 MHz)




¹³C-NMR spectrum of **3r** (CDCl₃, 150 MHz)





IR spectrum of **3r**




HRMS spectrum of **3r**




¹H-NMR spectrum of **3s** (CDCl_3 , 600 MHz)




¹³C-NMR spectrum of **3s** (CDCl₃, 150 MHz)





IR spectrum of **3s**




HRMS spectrum of **3s**




¹H-NMR spectrum of **4a** (CDCl₃, 600 MHz)



¹³C-NMR spectrum of **4a** (CDCl₃, 150 MHz)



IR spectrum of **4a**



HRMS spectrum of **4a**

